Shares of ImmuPharma plc (LON:IMM – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 5.63 and traded as low as GBX 3.60. ImmuPharma shares last traded at GBX 3.74, with a volume of 1,354,646 shares traded.
ImmuPharma Price Performance
The company’s fifty day moving average price is GBX 4.33 and its two-hundred day moving average price is GBX 5.63. The firm has a market cap of £23.33 million, a PE ratio of -10.11 and a beta of 3.00.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 1,397.44% and a net margin of 3,519.56%. As a group, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
